Dendorfer A, Wolfrum S, Schäfer U, Stewart J M, Inamura N, Dominiak P
Institute of Experimental and Clinical Pharmacology and Toxicology, Medical University of Lübeck, Lübeck, Germany.
Hypertension. 2000 Jan;35(1 Pt 1):32-7. doi: 10.1161/01.hyp.35.1.32.
Inhibitors of angiotensin I-converting enzyme (ACE) are very efficacious in the potentiation of the actions of bradykinin (BK) and are able to provoke a B(2) receptor-mediated vasodilation even after desensitization of this receptor. Because this activity cannot be easily explained only by an inhibition of kinin degradation, direct interactions of ACE inhibitors with the B(2) receptor or its signal transduction have been hypothesized. To clarify the significance of degradation-independent potentiation, we studied the vasodilatory effects of BK and 2 degradation-resistant B(2) receptor agonists in the isolated rat heart, a model in which ACE and aminopeptidase P (APP) contribute equally to the degradation of BK. Coronary vasodilation to BK and to a peptidic (B6014) and a nonpeptidic (FR190997) degradation-resistant B(2) agonist was assessed in the presence or absence of the ACE inhibitor ramiprilat, the APP inhibitor mercaptoethanol, or both. Ramiprilat or mercaptoethanol induced leftward shifts in the BK dose-response curve (EC(50)=3.4 nmol/L) by a factor of 4.6 or 4.9, respectively. Combined inhibition of ACE and APP reduced the EC(50) of BK to 0.18 nmol/L (ie, by a factor of 19) but potentiated the activity of B6014 (EC(50)=1.9 nmol/L) only weakly without altering that of FR190997 (EC(50)=0.34 nmol/L). Desensitization of B(2) receptors was induced by the administration of BK (0.2 micromol/L) or FR190997 (0.1 micromol/L) for 30 minutes; the vascular reactivity to ramiprilat or increasing doses of BK was tested thereafter. After desensitization with BK, but not FR190997, an additional application of ramiprilat provoked a B(2) receptor-mediated vasodilation. High BK concentrations were still effective at the desensitized receptor. The process of desensitization was not altered by ramiprilat. These results show that in this model, all potentiating actions of ACE inhibitors on kinin-induced vasodilation are exclusively related to the reduction in BK breakdown and are equivalently provoked by APP inhibition. The desensitization of B(2) receptors is overcome by increasing BK concentrations, either directly or through the inhibition of ACE. These observations do not suggest any direct interactions of ACE inhibitors with the B(2) receptor or its signal transduction but point to a very high activity of BK degradation in the vicinity of the B(2) receptor in combination with a stimulation-dependent reduction in receptor affinity.
血管紧张素I转换酶(ACE)抑制剂在增强缓激肽(BK)的作用方面非常有效,即使在该受体脱敏后,也能够引发B(2)受体介导的血管舒张。由于仅通过抑制激肽降解难以轻易解释这种活性,因此有人推测ACE抑制剂与B(2)受体或其信号转导存在直接相互作用。为了阐明不依赖降解的增强作用的意义,我们研究了BK和2种抗降解的B(2)受体激动剂在离体大鼠心脏中的血管舒张作用,在该模型中,ACE和氨肽酶P(APP)对BK的降解作用相当。在存在或不存在ACE抑制剂雷米普利拉、APP抑制剂巯基乙醇或两者的情况下,评估冠状动脉对BK以及对一种肽类(B6014)和一种非肽类(FR190997)抗降解B(2)激动剂的舒张反应。雷米普利拉或巯基乙醇分别使BK剂量-反应曲线(EC(50)=3.4 nmol/L)向左移位4.6倍或4.9倍。联合抑制ACE和APP可将BK的EC(50)降至0.18 nmol/L(即降低19倍),但仅轻微增强B6014(EC(50)=1.9 nmol/L)的活性,而不改变FR190997(EC(50)=0.34 nmol/L)的活性。通过给予BK(0.2 μmol/L)或FR190997(0.1 μmol/L)30分钟诱导B(2)受体脱敏;此后测试血管对雷米普利拉或递增剂量BK的反应性。在用BK而非FR190997脱敏后,再次应用雷米普利拉会引发B(2)受体介导的血管舒张。高浓度的BK在脱敏受体处仍然有效。脱敏过程不受雷米普利拉的影响。这些结果表明,在该模型中,ACE抑制剂对激肽诱导的血管舒张的所有增强作用均仅与BK降解的减少有关,并且APP抑制也能同等程度地引发这种增强作用。通过直接增加BK浓度或通过抑制ACE可克服B(2)受体的脱敏。这些观察结果并未表明ACE抑制剂与B(2)受体或其信号转导存在任何直接相互作用,而是表明在B(2)受体附近BK降解活性非常高,同时受体亲和力存在刺激依赖性降低。